Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib + Chemotherapy in R/R Pediatric ALL and LBL (HEM-iSMART Sub-protocol D)
NCT05658640Phase 2Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Nov 2023
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of trametinib in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at 3 years and Best Overall Response Rate at 6 years. Started Nov 2023; status: recruiting.
02
Drugs
trametinib
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT05658640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05658640.